A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

Oxford BioMedica

Status and phase: Active, not recruiting; Phase 1

Conditions: Age-Related Macular Degeneration

Treatments: Drug: RetinoStat

Study type: Interventional

Funder types: Industry

Identifiers

NCT01678872

RS1/002/11

Details and patient eligibility

About

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Enrollment: 18 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have received a subretinal injection of RetinoStat
• Must have been enrolled in Protocol RS1/001/10

Exclusion criteria

• Did not receive RetinoStat® as part of the RS1/001/10 protocol

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

Long Term Follow up

Other group

Description:

Long Term follow up of patients who received RetinoStat in a previous study.

Treatment:

Drug: RetinoStat